Shares of pharmaceutical companies dropped early Monday after President Donald Trump said he would lower the cost of ...

But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...

On Sunday, U.S. President Donald Trump changed that precedent, announcing that he would sign an executive order Monday to ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

The company disclosed revenue of $13.7 billion and adjusted earnings of $0.92 per share, compared to consensus estimates of ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, “which we are unable ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...